Defaecation, intestinal fluid accumulation and motility in rodents: Implications of cannabinoid CB1 receptors

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 359, Issue 1, 1999, Pages 65-70

  Izzo, Angelo A ^a   Mascolo, Nicola ^b   Borrelli, Francesca ^a   Capasso, Francesco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cannabinoid; Defaecation; Intestinal motility; Intestinal secretion; Small intestine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ATROPINE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NOLPITANTIUM; RIMONABANT; SAREDUTANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DEFECATION; GASTROINTESTINAL TRANSIT; GUINEA PIG; INTESTINE FLUID; INTESTINE MOTILITY; INTESTINE SECRETION; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR BINDING; RODENT;

EID: 0033001599     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005325     Document Type: Article

References (31)

1. 2 and colchicine on the intestinal fluid volume. Naunyn Schmiedebergs Arch Pharmacol 301:195-199
2. Brown DR, Miller RJ (1991) Neurohormonal control of fluid and electrolyte transport in intestinal mucosa. In: Field M, Frizzel RA (cd) Handbook of physiology. The gastrointestinal system IV. Gastrointestinal physiology: absorptive and secretory process of the intestines. American Physiological Society, Bethesda, pp 527-589
3. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D (1997) Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 340:R7-R8
4. Colombo R, Agabio R, Lobina C, Reali R, Gessa GL (1998) Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 344:67-69
5. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126
6. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594
7. Courts AA, Pertwee RG (1997) Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 121:1557-1566
8. Croci T, Bianchetti A (1992) Stimulation of faecal excretion in rats by α-adrenergic antagonists. J Pharm Pharmacol 44:358-360
9. Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand J-P, Manara L (1997) Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol 121:375-380
10. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
11. 2 receptors rat colonic hypersecretion induced by interleukin 1β: role of nitric oxide. Gastroenterology 109:483-489
12. Furness JB, Costa M, Eckstein F (1983) Neurones localized with antibodies against choline acetyltransferase in the enteric nervous system. Neurosci Lett 40:105-109
13. Gérard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279:129-134
14. Gifford AN, Ashby CR (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 277:1431-1436
15. 2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339:53-61
16. Holzer-Petsche U (1995) Tachykinin receptors in gastrointestinal motility. Regul Pept 57:19-42
17. G-nitro-L-arginine methyl ester modulates intestinal secretion and motility produced by carbachol. Eur J Pharmacol 271;31-35
18. 1 receptors. Br J Pharmacol 124:1363-1368
19. Kaminski NE, Abood M, Kessler FK, Martin BR, Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736-742
20. 2 receptors. Br J Pharmacol 124:619-622
21. Mascolo N, Izzo AA, Barbato F, Capasso F (1993) Inhibitors of nitric oxide synthetase prevent castor-oil-induced diarrhoea in the rat. Br J Pharmacol 108:861-864
22. Matsuda LA, Lolait SJ, Brownstein BJ, Young AC, Bonner TL (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
23. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
24. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
25. 2 receptors. Pharmacol Ther 74:129-180
26. 1 receptors in guinea-pig small intestine. Br J Pharmacol 118:2199-2205
27. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubriè P, Breliere JC, Le Fur G (1995) Biochemical and pharmacological characterisazion of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947
28. Robert A, Nezamis JE, Lancaster C, Hanchar AJ, Klepper MS (1976) Enteropooling assay: a test for diarrhoea produced by prostaglandins. Prostaglandins 11:809-828
29. 1 cannabinoid receptor antagonist SR141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58:PL103-PL110
30. Schirgi-Degen A, Beubler E (1995) Significance of nitric oxide in the stimulation of intestinal fluid absorption in the rat jejunum in vivo. Br J Pharmacol 114:13-18
31. 1 cannabinoid receptor antagonist, SR141716. Psychopharmacology 126:165-172